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Abstract 
Objectives – Most types of population-based cancer screening require repeat participation to 
be effective.  This study investigated predictors of repeat participation in the NHS Bowel 
Cancer Screening Programme (BCSP).   
Methods – The BCSP in England offers biennial colorectal cancer screening using a guaiac 
Faecal Occult Blood test (gFOBt) from age 60 to 74.  This analysis included 62,081 
individuals aged 60-64 at the time of the first invitation (R1).  The main outcome was repeat 
participation at their second (R2) or third (R3) invitation.  Behavioural measures derived from 
screening records included late return of the gFOBt kit, compliance with follow-up 
investigations and previous screening participation.  Other potential predictors of repeat 
participation included results of individual test kit analysis (normal, weak positive, strong 
positive, spoilt) and the definitive result of the gFOBt screening episode (normal or 
abnormal).  Age, sex and socioeconomic deprivation were also recorded.  
Results – Overall repeat uptake was 86.6% in R2 and 88.6% in R3.  Late return of the test 
kit was consistently associated with lower uptake (R2: 82.3% vs. 88.6%, p<.001; R3: 84.5% 
vs. 90.5%, p<.001).  A definitive abnormal gFOBt result in the previous screening episode 
was a negative predictor of repeat uptake (R2: 61.4% vs. 86.8%, p<.001; R3: 65.7% vs. 
88.8%, p<.001).  Weak positive (R2: 76.9% vs. 86.8%, p<.001; R3: 81.7% vs. 88.8%, p<.05) 
and spoilt test kits (R2: 79.0% vs. 86.6%, ns.; R3: 84.2% vs. 92.2%, p<.05) were associated 
with lower repeat uptake, but were not consistently independent predictors in all invitation 
rounds or subgroups.  Among those with a definitive abnormal gFOBt result, non-compliance 
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with follow-up in a previous screening episode was also associated with lower repeat uptake 
(R2: 24.3% vs. 67.1%, p<.001; R3: 43.2% vs. 69.9%, p<.001). 
Conclusions – Behavioural markers and test results from previous screening episodes have 
been implicated in subsequent gFOBt uptake.   
Keywords: Colorectal cancer screening; repeat screening; behavioural markers; reminders; 
weak positives; abnormal results; colonoscopy attendance  
Introduction 
Most tests for population-based cancer screening rely on repeated participation for optimal 
public health outcomes.  Since 2006, the NHS Bowel Cancer Screening Programme (BCSP) 
in England has invited men and women aged 60-69 (currently extended to 74) who are 
registered with a general practitioner (GP) to complete a guaiac-based faecal occult blood 
test (gFOBt) every two years.  Randomised controlled trials have shown that regular, 
repeated screening with gFOBt reduces colorectal cancer (CRC) mortality by up to 25% 
among participants (Hewitson et al, 2008; Scholefield et al, 2002).  Due to the low sensitivity 
of gFOBt, repeated participation is extremely important for the effectiveness of FOB 
screening (Soares-Weiser et al, 2007).   
 
Encouragingly, repeat uptake among people who have previously responded to a screening 
invitation is generally high.  Uptake of the first repeat screening invitation was around 87% in 
a recent study of the NHS BCSP (Lo et al, 2014).  High repeat uptake rates were also 
reported in a Spanish CRC pilot programme (87%; Garcia et al, 2012), an Australian pilot 
programme (80%; Cole et al, 2012) and a Dutch pilot programme (85%; Denters et al, 2013).  
However, the small amount of attrition at each round adds up across several screening 
rounds.  Consistent screening uptake over three rounds was only 44% in the NHS BCSP’s 
Southern Hub in England (Lo et al, 2014) and 39.2% in an earlier pilot study in Scotland 
(Steele et al, 2014).  Major factors known to contribute to attrition are an irregular screening 
participation history and being more socioeconomically deprived (Lo et al, 2014).   
 
Some other characteristics of an individual’s previous screening episode(s) also have been 
identified as risk factors for non-response to repeat screening invitations.  The need for a 
reminder prior to test kit return in the previous round was negatively associated with 
subsequent screening uptake in the Spanish pilot (Garcia et al, 2012).  Research on 
procrastination in general suggests that task aversiveness, self-efficacy and other person-
related characteristics could contribute to delayed action (Steel, 2007).  Late kit return is 
therefore a likely indicator of the degree of adversity an individual experiences in completing 
the test.  Possible causes include an aversion to stool sampling (Consedine et al, 2011) and 
general life difficulties (Power et al, 2008).      
 
The need for multiple gFOBts within one screening episode, most commonly because the 
first test kit gave a weak positive result (also known as inconclusive or unclear test results), 
may lead to incomplete gFOBt screening within one episode (Lo et al, 2014).  In the 
Australian and Spanish pilot studies, weak positives and a definitive abnormal FOB result 
were also associated with lower repeat uptake (Cole et al, 2012; Garcia et al, 2012).  
However, it is unknown whether factors related to the experience of gFOBt screening (i.e. 
late kit return and test results) are predictors of repeat uptake independent of other known 
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predictors, including sociodemographics and previous screening participation (Cole et al, 
2012; Denters et al, 2013; Garcia et al, 2012; Lo et al, 2014).   
 
Follow-up of abnormal gFOBt results (most commonly a colonoscopy) is integral to the 
success of a gFOBt screening programme (Smith et al, 2013) and determinants of follow-up 
colonoscopy compliance have been studied elsewhere (Morris et al, 2012).  However, to our 
knowledge, no previous studies have examined the role of follow-up after a definitive 
abnormal gFOBt result in subsequent gFOBt uptake.      
 
At the time of the first biennial invitation, only sex, age and postcode of invitees are known.  
However, as more previous screening episode data become available with each biennial 
invitation round, an increasingly detailed picture of each invitee emerges.  Examining 
previous screening episode patterns over a higher number of invitation rounds has the 
potential to generate powerful insights, which could be used to promote repeat uptake and 
improve communication with screening invitees.  Studies to date have only examined the 
relationship between first screening episode characteristics and the first repeat screening 
(Cole et al, 2012; Garcia et al, 2012).  It is not known if factors related to previous screening 
experience(s) remain useful indicators of individuals ‘at risk’ of dropout after the first repeat 
screening.  The present paper examines the role of previous screening episodes in repeat 
screening uptake using data from three biennial invitation rounds of the NHS BCSP.      
Methods 
Colorectal Cancer Screening in England 
The NHS BCSP in England provides CRC screening using a gFOBt kit that is completed at 
home and sent back in a freepost envelope.  A pre-invitation letter is sent eight days before 
the test kit (hema-screen, Immunostics Inc, USA).  To complete the test, two faecal samples 
from three consecutive stools are applied to three pairs of application windows in turn.  
Invitees who do not return the test kit are sent a reminder 28 days after the test kit was 
mailed.  Test kits are returned to a laboratory where each window is tested for the presence 
of blood.   
 
Participants who return a test kit with five or six positive windows (a ‘strong positive’ and thus 
a definitive ‘abnormal’ result) are offered a consultation with a Specialist Screening 
Practitioner (SSP) to discuss a follow-up examination (usually colonoscopy).  If the first test 
kit has one to four positive windows (a ‘weak positive’ or ‘unclear’ result), a repeat gFOBt is 
required.  The participant is referred to an SSP if any windows on a second or a third test kit 
are positive (a definitive ‘abnormal’ result).  If a second and third test kit both yield a negative 
result (a definitive ‘normal’ result), the individual is referred back to routine biennial 
screening.  A repeat gFOBt is also required when a test kit is designated ‘spoilt’ (i.e. 
inadequate or undated sample collection) or ‘technically failed’ (i.e. laboratory-based reading 
error). 
 
Sample 
The analysis used anonymised data from the Southern Hub of the NHS BCSP.  Each year, 
the Southern Hub invites about 1.1 million people in the south of England (excluding 
London).  
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All people (n=62,099) aged 60-64 years at the time of the first invitation (R1) to screening 
between September 2006 - February 2008 were included in the dataset.  The specified age 
range ensured that individuals were age-eligible for screening over three biennial invitations 
rounds, irrespective of the age extension.  Three invitation rounds therefore refers to a 
cohort of people who have received three biennial invitations (R1, R2, R3) in which they 
may, or may not, have participated.  Follow-up of invitees until December 2012 allowed for a 
minimum of three months for a response after invitation, any further investigations and minor 
adjustments made to the timing of screening invitations (‘invitation smoothing’) for each of 
the three rounds (BCSP Southern Hub, 2011).  Individuals may not receive three invitations 
for reasons that include clinical status, death, relocation outside the catchment area of the 
Hub or a written request declining further screening invitations.  After exclusion of eighteen 
people because of incomplete or ambiguous screening episode records, 62,081 cases were 
included in the analysis.1  Of the 62,081 included cases who received a first biennial 
screening invitation, 58,531 received a second invitation of whom 34,856 were invited for 
repeat screening (i.e. responders in R1).  A third invitation was sent to 55,028 cases of 
whom 38,373 were invited for repeat screening (i.e. responders in R1 and/or R2).   
 
Figure 1 illustrates the number of people receiving a screening invitation in each of the three 
biennial rounds.  The sample eligible for repeat screening in the second round (R2) 
consisted of participants who had responded to the first screening invitation (R1).  
Participants in repeat screening in the third round (R3) consisted of three subgroups 
(‘Consistent Screeners’, ‘Dropouts’ and ‘Late Entrants’), which varied by previous screening 
participation.  Box 1 defines each R3 subgroup by previous screening participation and 
states the ‘last screening episode’ for each subgroup.  The last screening episode refers to 
the last active screening round of any given individual.  Uptake in each round and uptake by 
subgroup are described in Table 1A and 1B respectively.  A previous publication has 
discussed uptake by sociodemographics and previous screening participation in more detail 
(Lo et al, 2014).  
 
Measures 
gFOBt screening uptake – whether an invited individual was adequately screened (i.e. 
received a definitive gFOBt result).  Uptake in previous invitation rounds was used to define 
subgroups in R3 (Box 1).     
 
Late return of gFOBt kit in the previous screening episode – the sent and return dates of the 
first gFOB test kit in each screening episode were used to calculate the number of days an 
individual had taken to return the test kit.  The outcome was dichotomised into a late return 
variable (>28 days).   
 
gFOBt results in the previous screening episode – the number of completed test kits in the 
last screening episode and the test result of each completed kit (i.e. normal, weak positive, 
strong positive, spoilt, technical failure).  Technical failures were not examined further due to 
                                                          
1
A screening episode record was considered ambiguous if there was a mismatch between the records 
of the individual’s screening uptake, the number of test kits completed and test results of each 
completed kit (e.g. adequately screened, but only one completed test kit with a weak positive result).   
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their low occurrence (n=20 in R2; n=14 in R3).  For individuals who were adequately 
screened, the definitive gFOBt result was also recorded.   
 
Follow-up compliance – for people who had received a definitive abnormal gFOBt result, 
attendance at the SSP appointment and colonoscopy (or another follow-up examination) 
was recorded.  A dichotomous variable for follow-up compliance was used and defined as 
failure to attend SSP OR colonoscopy/ other follow-up examination (0) and attendance of 
SSP AND colonoscopy/ other follow-up examination (1).    
 
Sociodemographics – sex, age at the time of invitation and a neighbourhood-level measure 
of socioeconomic deprivation (index of multiple deprivation [IMD] score 2004, based on the 
2001 Census; scale 0-80 with a score of 0 being the least deprived and 80 being the most 
deprived) were recorded for each individual (Office for National Statistics, 2004).   Some 
people received a subsequent invitation when they were more than two years older than at 
the previous invitation due to the precise timing of their birthdays, (very) late return of 
previous test kits, time elapsed until follow-up investigations and invitation smoothing 
practices.  Age was therefore divided into three categories (young, middle, old) per invitation 
round for the analysis.  The first two categories each represented a two-year time span, 
whereas the third category covered all older ages.   
 
Data Analysis 
Repeat screening uptake (where ‘uptake’ is defined as the proportion of the invited 
population that was adequately screened) and all predictors are described by biennial 
invitation round (R2, R3).  Repeat uptake, gFOBt-related predictors and follow-up 
compliance are also described for each subgroup in R3.   
 
Multivariable logistic regression analysis was used with repeat uptake as the outcome 
variable and gFOBt-related previous screening episode variables, sociodemographic 
variables and previous screening participation (only for uptake in R3) as explanatory 
variables.  Repeat uptake of each subgroup in R3 was also examined separately with 
gFOBt-related previous screening episode factors and sociodemographics as explanatory 
variables.  gFOBt-related previous screening episode predictors included late return of the 
test kit (>28 days), weak positives, spoilt test kits and a definitive abnormal gFOBt result.  
The sociodemographic predictors were age, sex and socioeconomic deprivation.  Variables 
derived from the last screening episode were used for all analyses, except for a late return 
variable based on both R1 and R2, which was used in the subgroup analysis for ‘Consistent 
Screeners’.   
 
The reference category for the weak positive effect differed between individuals with a 
definitive normal (ref. cat.: normal result for the first test kit) and a definitive abnormal (ref. 
cat.: strong positive result for the first test kit) gFOBt result.  Differences in the effect of weak 
positives between definitive normal and definitive abnormal individuals were therefore 
examined.  An interaction between weak positives and the definitive FOB test result was 
tested and included in the reported models if the interaction was statistically significant at the 
p<0.05 level.  Previous screening participation is associated with incomplete gFOBt 
screening due to multiple testing (Lo et al, 2014).  For this reason, interactions between 
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previous screening participation and weak positives/ spoilt test kits were also tested and 
reported if statistically significant.    
 
A simple logistic regression analysis was conducted to examine the effect of follow-up 
compliance on subsequent gFOBt screening uptake in R2 and R3 among individuals who 
had received a definitive abnormal gFOBt result in the previous screening episode.   
Results 
Neighbourhood-level socioeconomic deprivation was the only sociodemographic factor 
consistently associated with repeat uptake, independent of other sociodemographic and 
previous screening episode factors.  Being socioeconomically deprived was associated with 
lower repeat uptake in both R2 and R3 (p<.001; Table 2A).  Lower repeat uptake in R3 was 
consistently observed among Consistent Screeners (p<.001), Dropouts (p<.001) as well as 
Late Entrants (p<.01; Table 2B).  
Late return of test kit in the previous screening episode 
Repeat uptake in R2 was lower among those who, in the first round, had been late in 
returning their gFOBt kit and had received a reminder letter than those who had returned it 
within 28 days (82.3% vs. 88.6%, p<.001; Table 1A-2A).  Late return was also associated 
with lower uptake in R3 overall (84.5% vs. 90.5%, p<.001) and all R3 subgroups.   ‘Dropouts’ 
(58.1% vs. 61.1%, p<.05) and ‘Late Entrants’ (75.8% vs. 79.4%, p<.01; Table 1B-2B) had 
lower uptake in R3 if they had returned the kit late in their previous episode.  Late return had 
a graded effect on repeat uptake in R3 among ‘Consistent Screeners’, the only subgroup 
which had two previous screening episodes.  ‘Consistent Screeners’ who had returned the 
kit promptly in both R1 and R2 had an R3 uptake rate of 95.9%.  Those who had returned 
the kit late in either R1 (94.2%, p<.001) or R2 (93.0%, p<.001) were slightly less likely to 
respond in R3 than consistent prompt responders (95.9%, ref.).  ‘Consistent Screeners’ who 
had returned the kit late in both R1 and R2 were least likely to respond (91.1%, p<.001).  
gFOBt results in the previous screening episode 
A definitive abnormal gFOBt result in the previous screening episode was strongly 
associated with lower repeat uptake in R2 (61.4% vs. 86.6%, p<.001) and R3 (65.7% vs. 
88.8%, p<.001; Table 1A-2A).  The effect of a definitive abnormal result on uptake in R3 was 
similar among ‘Consistent Screeners’ (75.9% vs. 94.7%, p<.001), ‘Dropouts’ (30.7% vs. 
60.3%, p<.001) and ‘Late Entrants’ (58.8% vs. 78.4%, p<.01; Table 1B-2B).  
 
Repeat uptake in R2 was lower if the participant had received a weak positive result in the 
previous screening episode (76.9% vs. 86.8%, p<.001; Table 1A-2A).  In contrast, weak 
positives were not significantly associated with uptake in R3 (81.7% vs. 88.8%, ns.), 
although uptake figures showed a similar trend.  Among the R3 subgroups, weak positives 
were a significant independent predictor of uptake only among ‘Consistent Screeners’ 
(88.2% vs. 94.8%, p<.01; Table 1B-2B).  Weak positives were not a significant predictor of 
uptake for ‘Dropouts’ (54.6% vs. 60.1%, ns.) and ‘Late Entrants’ (70.6% vs. 78.3%, ns.).   
 
The effect of weak positives on subsequent repeat uptake in R2 interacted significantly with 
the definitive gFOBt result (p<.01; Table 1A-2A).  This interaction was not significant for 
overall repeat uptake in R3.  However, a significant interaction effect was observed among 
‘Consistent Screeners’ (p<.05) but no effect was found for ‘Dropouts’ and ‘Late Entrants’ 
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(Table 1B-2B).  Figure 2 illustrates the interaction effect.  Among individuals who had a 
definitive normal gFOBt result in the previous screening episode, repeat uptake in R2 
(81.6% vs. 86.9%, Crude OR = 0.67, 95% CI: 0.55 – 0.82, p<.001) and among ‘Consistent 
Screeners’ in R3 (92.2% vs. 94.8%, Crude OR = 0.65, 95% CI: 0.50 – 0.84, p<.01) was 
lower among those who had received a weak positive result than among those who had a 
normal (first test kit) result in the previous screening episode.  In contrast, among individuals 
who had a definitive abnormal gFOBt result, subsequent uptake in R2 was higher among 
individuals who had a weak positive result than those who had a strong positive (first test kit) 
result in the previous screening episode (63.8% vs. 44.1%, Crude OR = 2.23, 95% CI: 1.08 
– 4.61, p<.05).  A similar non-significant trend was observed among Consistent Screeners in 
R3 (76.8% vs. 68.6%, Crude OR = 1.52, 95% CI: 0.71 – 3.27, ns.).  The significant 
interactions in R2 and among Consistent Screeners in R3 (the largest subgroup in the third 
round) suggest that multiple testing within one screening episode due to weak positives can 
be a deterrent to future screening if the weak positive had turned out to be a ‘false alarm’.   
 
Spoilt test kits were an independent, negative predictor of overall repeat uptake only in R3 
(80.7% vs. 88.6%, p<.05; Table 1A-2A).  Uptake figures for repeat screening in R2 (spoilt: 
79.0% vs. no spoilt: 86.6%, ns.; Table 1A-2A)  showed a similar trend towards lower uptake, 
but were not statistically significant.  This suggests that the multivariable analysis was 
underpowered to detect moderate-sized differences, as the number of people with spoilt test 
kits was low.  Spoilt test kits were therefore not included in the reported R3 subgroup 
analyses.   
 
Follow-up non-compliance in the previous screening episode 
Among individuals who returned to routine screening following a definitive abnormal gFOBt 
result, simple logistic regression analysis was used to examine the effect of follow-up 
compliance on subsequent screening uptake.  Subsequent uptake in R2 (24.3% vs. 67.1%, 
p<.001) and R3 (43.2% vs. 69.9%, p<.001) was significantly lower among people who had 
not complied with follow-up examinations in R1 than among those who had complied (Table 
1A-3A).  In the R3 subgroups, subsequent uptake among non-compliers was significantly 
lower than among compliers among ‘Consistent Screeners’ (61.8% vs. 77.6%, p<.05) and 
‘Dropouts’ (9.1% vs. 39.6%, p<.05; Table 1B-3B).  Subsequent uptake was not significantly 
different among ‘Late Entrants’, although results were in a similar direction (50.0% vs. 
61.3%, ns.; Table 1B-3B).   
 
Discussion 
Previous screening episode factors related to both the gFOBt and follow-up are predictive of 
subsequent gFOBt uptake, independent of sociodemographic and other previous screening 
episode factors.  This is remarkable in the light of high overall uptake of repeat screening 
invitations.  Socioeconomic deprivation was the only socio-demographic factor consistently 
associated with repeat uptake, independent of previous screening episode factors.       
 
Similar to previous findings from a Spanish pilot programme (Garcia et al, 2012), late return 
of the previous test kit (>28 days) was consistently associated with lower uptake in R2 and 
R3.  Most interestingly, the negative association between late return and subsequent uptake 
was graded among ‘Consistent Screeners’, who had all participated twice before.  
‘Consistent Screeners’ who had responded promptly in both episodes were most likely to 
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respond in R3, followed by those who had returned a kit late once, and finally, those who 
had returned the kit late in both previous screening episodes.  The fact that effect of late 
return was not smaller among ‘Consistent Screeners’ compared with ‘Dropouts’ and ‘Late 
Entrants’ is also noteworthy.  It suggests that more frequent participation in the past does not 
help overcome difficulties related to late kit return, such as task aversiveness (Consedine et 
al, 2011; Steel, 2007).   
 
Future studies should investigate whether planning methods, such as implementation 
intentions, could promote continued uptake among people with a history of late kit returns 
(Gollwitzer & Sheeran, 2006).  Implementation intentions are often used to promote self-
regulation and help people overcome anticipated barriers by formulating “if-then” plans 
(Gollwitzer, 1999).  If this is an effective method, the individual-level data available from the 
NHS database could be used to target planning interventions specifically to this at-risk 
group.     
 
Among those who remained eligible for routine screening, a definitive abnormal gFOBt result 
was strongly associated with lower subsequent uptake, consistent with results from an 
Australian pilot (Cole et al, 2012).  Further research is needed to examine if this is due to a 
lack of perceived necessity to engage with further gFOBt screening after a colonoscopy or 
another type of follow-up investigation, a more general negative attitude change or other 
reasons (e.g. patient experience of the follow-up investigation).  Also consistent with 
previous studies (Cole et al, 2012; Garcia et al, 2012), a weak positive test result in the 
previous screening episode was a negative predictor of repeat uptake in R2 and uptake 
among Consistent Screeners in R3.  This suggests that the requirement for multiple gFOB 
testing within one screening episode can be a deterrent to subsequent screening.  The 
results also show tentative evidence of an association between spoilt test kits (another 
reason for multiple gFOB testing) and lower subsequent uptake.   
 
A subgroup analysis showed that weak positives only had a negative effect on subsequent 
uptake among individuals with a definitive normal gFOBt result.  Screening with multiple 
gFOBt kits therefore appears to be a deterrent only when the final test result was normal, 
possibly due to a perceived lack of benefit resulting from screening.  Consistent with this 
hypothesis, a breast screening study showed that experienced pain was negatively 
associated with re-attendance only if the individual had previously received a false positive 
(vs. negative) screening outcome (Hofvind et al, 2003).  In other words, individuals might be 
more resilient to adverse events if the perceived usefulness of screening remains 
unchallenged.   
 
Due to sample size limitations, the current study could not examine the effect of diagnostic 
outcomes from follow-up examinations on subsequent uptake among individuals who were 
referred back to routine screening.  Future national studies should examine the role of 
diagnostic outcomes, as it could add further evidence to whether screening test outcomes 
affect (perceived usefulness of) repeat screening participation.  National-level studies could 
also use routinely collected data of patient-reported outcomes to address the potential role of 
patient experiences with follow-up investigations in subsequent gFOBt uptake.  Qualitative 
research on the appraisal of screening test results would also be a valuable addition to the 
current evidence base.  This could inform communication about test results and reduce the 
potential negative impact of test results on subsequent screening uptake.  Although some 
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adverse screening events are inevitable, the use of Faecal Immunochemical Tests for 
haemoglobin (FIT) would be one strategy to greatly reduce multiple testing, thus avoiding the 
adverse consequences resulting from weak-positive gFOBt results.  A recent FIT study 
reported higher consistent uptake over three rounds (54%) than those reported for gFOBt 
uptake (39-44%) (Kapidzic et al, 2014; Lo et al, 2014; Steele et al, 2014).    
 
Compliance with follow-up examinations was also associated with subsequent gFOBt 
screening uptake in R2 and among ‘Consistent Screeners’ and ‘Dropouts’ in R3 (if people 
remained eligible for routine screening).  The figures for ‘Late Entrants’ showed similar 
trends but failed to reach statistical significance, possibly due to the smaller sample size in 
this subgroup.  This indicates that some people with an abnormal gFOBt result do not 
comply with follow-up nor do they return to routine screening.  Although few in number, they 
are part of a small, high-risk group which is more likely to reap tangible health benefits from 
full compliance with all screening recommendations.   
 
To conclude, although gFOBt repeat screening uptake was generally high, previous 
screening episode characteristics were associated with lower repeat uptake.  Late test kit 
return, a definitive abnormal gFOBt result and failure to comply with follow-up examinations 
in a previous screening episode were consistently and independently associated with lower 
repeat uptake.  Screening records and other data related to previous screening episodes 
could therefore be used to identify groups at higher risk of non-response to repeat screening 
invitations.  While previous screening episode factors often cannot be modified, tailored 
communication and assistance throughout the screening process could reduce the impact of 
the identified risk factors.  The present study has demonstrated the potential for information 
about screening trajectories to inform and streamline screening programmes through 
tailoring services and communication to the individual.  Future research should examine the 
full potential of data related to previous screening experiences to promote regular 
participation in CRC screening programmes.  
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Box 1. Definitions of subgroups in the third biennial invitation round (R3) 
Group Description Uptake 
in R1 
Uptake 
in R2 
Last 
screening 
episode 
Consistent Screeners 1st invitation to 2nd repeat screen  Yes Yes R2 
Dropouts 2nd invitation to 1st repeat screen  Yes No R1 
Late Entrants 1st invitation to 1st repeat screen  No Yes R2 
R1: first biennial invitation round; R2: second biennial invitation round  
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Table 1A: repeat screening uptake per biennial invitation round by previous screening episode factors in percentages with the denominator (n) 
 2nd biennial invitation round 
(R2) 
 
3rd biennial invitation round 
(R3) 
Total repeat screening uptake  86.55 (34,856) 88.55 (38,373) 
By previous screening episode factors   
Time to kit return    
     ≤28 days 88.64 (23,361) 90.48 (26,136) 
     >28 days 82.30 (11,495) 84.45 (12,237) 
Weak positives    
     None 86.81 (33,930) 88.82 (36,941) 
     One or more 76.89 (926) 81.70 (1,432) 
Definitive gFOBt result   
     Normal  86.75 (34,576) 88.84 (37,907) 
     Abnormal  61.43 (280) 65.67 (466) 
Spoilt kit   
     None 86.59 (34,651) 88.62 (38,067) 
     One or more 79.02 (205) 80.72 (306) 
Follow-up compliance   
     Not complied 24.32 (37) 43.24 (74) 
     Complied 67.08 (243) 69.90 (392) 
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Table 1B: repeat screening uptake in the third biennial invitation round per subgroup by previous screening episode factors in percentages with 
the denominator (n) 
 R3 Consistent Screeners 
 
R3 Dropouts R3 Late Entrants 
Total repeat screening uptake  94.53 (29,175) 59.82 (4,263) 78.03 (4,935) 
By previous screening episode factors 
Time to kit return     
     ≤28 days - 61.10 (2,414) 79.43 (3,039) 
     >28 days - 58.14 (1,849) 75.79 (1,896) 
     ≤28 days in R1 & R2 95.93 (15,739) - - 
     >28 days in R1 94.24 (4,944) - - 
     >28 days in R2  92.99 (4,451) - - 
     >28 days in R1 & R2 91.14 (4,041) - - 
Weak positives     
     None 94.77 (28,106) 60.05 (4,080) 78.32 (4,755) 
     One or more 88.21 (1,069) 54.64 (183) 70.56 (180) 
Definitive gFOBt result    
     Normal  94.73 (28,864) 60.34 (4,188) 78.35 (4,855) 
     Abnormal  75.88 (311) 30.67 (75) 58.75 (80) 
Follow-up compliance    
     Not complied 61.76 (34) 9.09 (22) 50.00 (18) 
     Complied 77.62 (277) 39.62 (53) 61.29 (62) 
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Table 2A: repeat screening uptake by invitation round: multivariable logistic regression results of sociodemographic and previous screening 
episode factors 
 2nd biennial invitation round 
(R2) 
3rd biennial invitation round 
(R3) 
 OR 95% CI OR 95% CI 
Sociodemographics     
Men 1.00 (ref.)  1.00 (ref.)  
Women 1.03 0.97 – 1.10 0.98 0.91 – 1.05 
IMD score (0-80) 0.98*** 0.98 – 0.99 0.99*** 0.98 – 0.99 
Age at 2nd invitation (62-70)     
     62-63 1.00 (ref.)  -  
     64-65 1.05 0.99 – 1.13 -  
     66+ 0.99 0.88 – 1.11 -  
Age at 3rd invitation (63-72)     
     64-65 -  1.00 (ref.)  
     66-67 -  0.94 0.88 – 1.01 
     68+ -  0.84** 0.74 – 0.95 
Previous screening episode factors     
Kit return – ≤28  days 1.00 (ref.)  1.00 (ref.)  
Kit return – >28 days 0.60*** 0.56 – 0.64 0.69*** 0.64 – 0.74 
Weak positives – none 1.00 (ref.)  1.00 (ref.)  
Weak positives – one or more 0.70*** 0.57 – 0.85 0.70* 0.56 – 0.88 
Definitive gFOBt result – normal 1.00 (ref.)  1.00 (ref.)  
Definitive gFOBt result – abnormal 0.12*** 0.06 – 0.23 0.27*** 0.21 – 0.35 
Spoilt kit – none  1.00 (ref.)  1.00 (ref.)  
Spoilt kit – one or more 0.73 0.52 – 1.03 0.71* 0.52 – 0.98 
Weak positive x definitive result  3.29** 1.54 – 7.06 -  
Previous uptake subgroups     
Consistent Screeners -  1.00 (ref.)  
Late Entrants -  0.21*** 0.19 – 0.23 
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Dropouts -  0.09*** 0.08 – 0.10 
Weak positive x previous uptake  -  1.40*** 1.16 – 1.67 
* p<.05; ** p<.01; *** p<.001 
Table 2B: repeat screening uptake in the third biennial invitation round per subgroup: multivariable logistic regression results of 
sociodemographic and previous screening episode factors 
 R3 Consistent Screeners R3 Dropouts 
 
R3 Late Entrants 
 OR 95% CI OR 95% CI OR 95% CI 
Sociodemographics       
Men 1.00 (ref.)  1.00 (ref.)  1.00 (ref.)  
Women 0.99 0.90 – 1.10 0.93 0.82 – 1.05 0.99 0.87 – 1.14 
IMD score (0-80) 0.98*** 0.98 – 0.99 0.99*** 0.98 – 0.99 0.99** 0.99 – 1.00 
Age at 3rd invitation (63-72)       
     64-65 1.00 (ref.)  1.00 (ref.)  1.00 (ref.)  
     66-67 0.94 0.85 – 1.05 0.92 0.81 – 1.05 0.95 0.83 – 1.10 
     68+ 0.76** 0.63 – 0.91 0.84 0.66 – 1.06 0.99 0.77 – 1.26 
Previous screening episode factors       
Kit return – ≤28 days -  1.00 (ref.)  1.00 (ref.)  
Kit return – >28 days -  0.85* 0.75 – 0.96 0.81** 0.70 – 0.93 
Kit return – ≤28 days in R1 & R2 1.00 (ref.)  -  -  
Kit return – >28 days in R1 0.69*** 0.60 – 0.80 -  -  
Kit return – >28 days in R2 0.55*** 0.48 – 0.64 -  -  
Kit return – >28 days in R1 & R2 0.43*** 0.37 – 0.49 -  -  
Weak positives – none 1.00 (ref.)  1.00 (ref.)  1.00 (ref.)  
Weak positives – one or more 0.66** 0.51 – 0.86 1.42 0.97 – 2.08 0.91 0.61 – 1.35 
Definitive gFOBt result – normal 1.00 (ref.)  1.00 (ref.)  1.00 (ref.)  
Definitive gFOBt result – abnormal 0.12*** 0.06 – 0.24 0.21*** 0.11 – 0.38 0.43** 0.25 – 0.74 
Weak positive x definitive result 2.44* 1.07 – 5.55 -  -  
* p<.05; ** p<.01; *** p<.001 
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Table 3A: repeat screening uptake by invitation round: simple logistic regression results of follow-up compliance in the previous screening 
episode  
 2nd biennial invitation round 
(R2) 
3rd biennial invitation round 
(R3) 
 OR 95% CI OR 95% CI 
Follow-up compliance in previous episode     
Follow-up – complied  1.00 (ref.)  1.00 (ref.)  
Follow-up – not complied 0.16*** 0.07 – 0.35 0.33*** 0.20 – 0.55 
*** p<.001 
 
 
Table 3B: repeat screening uptake in the third biennial invitation round per subgroup: simple logistic regression results of follow-up compliance 
in the previous screening episode  
 R3 Consistent Screeners R3 Dropouts 
 
R3 Late Entrants 
 OR 95% CI OR 95% CI OR 95% CI 
Follow-up compliance in previous episode       
Follow-up – complied  1.00 (ref.)  1.00 (ref.)  1.00 (ref.)  
Follow-up – not complied 0.47* 0.22 – 0.98 0.15* 0.03 – 0.72 0.63 0.22 – 1.82 
* p<.05 
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Figure 1: sample sizes in each biennial invitation round by previous uptake (in percentages of the initial sample) 
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Figure 2: % subsequent gFOBt uptake by weak positives and definitive gFOB result in a previous screening episode 
   
   Results of simple logistic regression analyses of weak positives as the predictor of subsequent uptake: 
   * p<.05; ** p<.01; *** p<.001  
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